Skip to main content
. 2021 Jan 22;13(3):400. doi: 10.3390/cancers13030400

Figure 5.

Figure 5

Structure of various models of incorporation of active compounds into SLNs: (a) solid solution (homogenous matrix) model, (b) drug-enriched shell model, (c) drug-enriched core model (Illustrated through Biorender.com).